Compare Ginkgo Bioworks Holdings Inc (DNA) vs PAGSEG Inc (PAGS) Price & Performance

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

PAGS trades at $10.81, up 2.81% today, with a bullish technical signal from moving averages. The stock shows strong valuation metrics with a P/E of 7.1 and P/S of 0.74, supported by a 10.45% net income margin and recent earnings beats. A dividend of $0.28 is scheduled for September 2026, enhancing income appeal. Revenue growth remains steady, with 2026 guidance maintained despite a challenging macro environment.

Outlook is positive with analyst consensus at Buy (62.5%) and a $10.70 price target, though risks include elevated credit losses and Brazilian interest rate volatility. The stock's low valuation and dividend yield present a value opportunity, but investors must monitor execution on credit quality and banking growth.